Standard & Poor's New And Revised Criteria Published During September 2011 Oct 11

  • ID: 1927978
  • October 2011
  • Standard & Poors
1 of 2

NEW YORK (Standard & Poor's) Oct. 3, 2011--Standard & Poor's Ratings Services published the following criteria articles during September 2011. Articles appear in chronological order. All are available on www.globalcreditportal.com and www.standardandpoors.com. For more information, contact the analysts listed on the articles. Criteria | Structured Finance | RMBS: Outlook Assumptions For The Australian Residential Mortgage Market (Sept. 1, 2011) Standard & Poor's published its outlook assumptions for the Australian residential mortgage market to support our view of loss expectations for archetypical mortgage pools. Our credit analysis of mortgage pools, which incorporates this outlook and expected loss scenario, reflects the loss expectation for the archetypical RMBS pool, and our view that the baseline credit enhancement level associated with a 'B' rating...

Action: General Comment

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.